Scilex Holding (SCLX) Stock Price, Financials & Analysis

Key Stats

Market Cap12.23 Mn

P/E-0.03

FCF (Yr)3.68 Mn

ROA (Yr)-163.37

EV to EBIT-0.01

Net Income (Yr)-402.49 Mn

Enterprise Value2.38 Mn

Add ratio to table…

About

Scilex Holding Co is an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain. The company markets three FDA approved products ZTlido for postherpetic neuralgia ELYXYB for acute migraine and GLOPERBA for gout prophylaxis. It also has a pipeline of product candidates including SEMDEXA for sciatica SP-103 for acute pain and SP-104 for fibromyalgia. Revenue is…

Revenue is generated primarily from sales of its approved products ZTlido ELYXYB and GLOPERBA to wholesalers pharmacies and health care providers. The company also earns revenue from contract manufacturing services and royalties related to its licensed products. While the firm has adopted a cryptocurrency treasury strategy it does not currently treat digital assets as a primary source of operating revenue.

Within the pain management market the company occupies a niche focused on non opioid therapies that address unmet needs in neuropathic pain migraine and gout. Its lead product ZTlido competes against branded lidocaine patches such as Lidoderm and generic versions from manufacturers like Teva Mylan and Par Pharmaceutical. ELYXYB faces competition from other migraine treatments including NSAIDs triptans and CGRP inhibitors. GLOPERBA is the only FDA approved liquid colchicine product and competes with generic colchicine formulations and uric acid lowering agents such as allopurinol. The company’s competitive advantages stem from its proprietary drug delivery technology its strong patent portfolio and its ability to secure formulary placement with major payers.

The company sells its products through a network of national and regional wholesalers including McKesson Cardinal Health and AmerisourceBergen. These distributors supply retail chains such as CVS Walgreens Rite Aid and independent pharmacies. Formulary coverage has been secured with major payers including CVS Caremark Aetna Cigna Express Scripts United Healthcare Optum Rx Anthem BCBS and various state Medicaid programs.

How Scilex Holding ranks

Ranked against the 671 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.03xMedian 17.8x 2^nd
P/FCFNegative free cash flow −0.70xMedian 21.0x 18^th
P/Operating cash flowNegative operating cash flow −0.70xMedian 16.8x 17^th
P/S 0.38xMedian 8.14x 95^th
P/BNegative shareholder equity −0.04xMedian 2.02x Not meaningful —
P/Tangible bookNegative tangible equity −0.03xMedian 2.24x Not meaningful —
EV/EBITDANegative EBITDA −0.26xMedian 15.7x 8^th
EV/EBITNegative EBIT −0.26xMedian 20.9x 9^th
EV/Revenue 2.91xMedian 5.92x 67^th
EV/FCFNegative free cash flow −5.39xMedian 22.0x 48^th
EV/Operating cash flowNegative operating cash flow −5.39xMedian 18.3x 48^th
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.36 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −28.5%Median 11.0% 23^rd
Revenue CAGR (3Y) −12.0%Median 10.4% 24^th
Gross profit growth (1Y) −43.5%Median 11.8% 16^th
Gross profit CAGR (3Y) −16.8%Median 12.3% 16^th
Operating income growth (1Y) −271%Median −1.6% 4^th
Operating income CAGR (3Y) −65.9%Median 1.4% 6^th
Net income growth (1Y) −509%Median −3.3% 5^th
Net income CAGR (3Y) −109%Median −0.1% 2^nd
EPS growth (1Y) −472%Median 22.4% 5^th
EPS CAGR (3Y) −457%Median 25.9% 1^st
Operating cash flow growth (1Y) −183%Median −0.4% 5^th
Operating cash flow CAGR (3Y) 4.2%Median 2.1% 54^th
Free cash flow growth (1Y) −183%Median −0.1% 5^th
Free cash flow CAGR (3Y) 4.2%Median 2.5% 52^nd

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 55.6%Median 74.2% 29^th
EBITDA margin −1,101%Median −214% 30^th
Operating margin −1,135%Median −213% 30^th
Pretax margin −1,468%Median −205% 28^th
Net margin −1,416%Median −196% 27^th
FCF margin −54.0%Median −181% 61^st
Operating cash flow margin −54.0%Median −175% 61^st
Return on equity —Median −54.7% No data —
Return on assets −134%Median −41.1% 16^th
Return on invested capital —Median −5.3% No data —
Return on capital employed —Median −47.8% No data —
Asset turnover 0.12xMedian 0.18x 43^rd
Cash conversion (OCF / net income)Net income is not positive 0.03xMedian 1.14x Not meaningful —
Stock comp / revenue 50.9%Median 29.2% 44^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 31.9%Median 20.0% 34^th
Debt / equityNegative shareholder equity −0.26xMedian 0.27x Not meaningful —
Net debt / EBITDAEBITDA is not positive −0.23xMedian 1.22x Not meaningful —
Debt / FCFFree cash flow is not positive −4.73xMedian 3.65x Not meaningful —
Liabilities / assets 222%Median 32.3% 6^th
Equity / assetsNegative shareholder equity −122%Median 67.7% 6^th
Interest coverage −22.2xMedian −10.0x 42^nd
Current ratio 0.07xMedian 4.37x 2^nd
Quick ratio 0.04xMedian 3.65x 4^th
Cash ratio 0.00xMedian 3.35x 1^st
Altman Z-score −12.9Median −0.80 19^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,265.06 Bn	45.87	14.63	49.50 Bn
2	JNJ	Johnson & Johnson	677.68 Bn	42.10	6.82	44.65 Bn
3	ABBV	AbbVie Inc.	516.41 Bn	49.93	7.82	80.90 Bn
4	MRK	Merck & Co., Inc.	362.94 Bn	147.96	5.39	53.78 Bn
5	NVS	Novartis Ag	316.13 Bn	24.57	6.03	9.59 Bn
6	AZN	Astrazeneca Plc	289.36 Bn	33.25	5.34	32.35 Bn
7	AMGN	Amgen Inc	250.76 Bn	26.70	6.45	54.01 Bn
8	SCLX	Scilex Holding Co	0.01 Bn	-0.03	0.39	0.08 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,265.06 Bn

45.87

14.63

49.50 Bn

JNJ

Johnson & Johnson

677.68 Bn

42.10

6.82

44.65 Bn

ABBV

AbbVie Inc.

516.41 Bn

49.93

7.82

80.90 Bn

MRK

Merck & Co., Inc.

362.94 Bn

147.96

5.39

53.78 Bn

NVS

Novartis Ag

316.13 Bn

24.57

6.03

9.59 Bn

AZN

Astrazeneca Plc

289.36 Bn

33.25

5.34

32.35 Bn

AMGN

Amgen Inc

250.76 Bn

26.70

6.45

54.01 Bn

SCLX

Scilex Holding Co

0.01 Bn

-0.03

0.39

0.08 Bn

Scilex Holding SCLX

About

How Scilex Holding ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Scilex Holding SCLX

About

How Scilex Holding ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password